Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.

Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Abstract Text:

Taishi Nakamura,Eiichiro Yamamoto,Keiichiro Kataoka,Takuro Yamashita,Yoshiko Tokutomi,Yi-Fei Dong,Shinji Matsuba,Hisao Ogawa,Shokei Kim-Mitsuyama,Taishi Nakamura,Eiichiro Yamamoto,Keiichiro Kataoka,Takuro Yamashita,Yoshiko Tokutomi,Yi-Fei Dong,Shinji Matsuba,Hisao Ogawa,Shokei Kim-Mitsuyama,

The effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on hypertensive cardiovascular injury is unknown. We examined the effect of pioglitazone on hypertensive cardiovascular injury and the significance of combination of pioglitazone with angiotensin type 1 receptor blocker. Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovasucular injury. Pioglitazone, without lowering blood pressure, significantly suppressed cardiac inflammation and fibrosis and reduced vascular endothelial dysfunction, and these beneficial effects were associated with the reduction of superoxide by inhibition of cardiovascular NADPH oxidase. Thus, pioglitazone protects against hypertensive cardiovascular injury, by inhibiting reactive oxygen species (ROS). Combination of pioglitazone and candesartan suppressed cardiac hypertrophy, inflammation, and interstitial fibrosis of SHRSP to a greater extent than either monotherapy, and reduced vascular endothelial dysfunction of SHRSP more than either monotherapy. Furthermore, more beneficial effects of their combination on cardiovascular injury were associated with more reduction of NADPH oxidase-mediated cardiovascular ROS. To elucidate the underlying molecular mechanism, we examined cardiovascular NADPH oxidase subunits. Pioglitazone monotherapy significantly attenuated cardiovascular p22(phox) and Rac1 in SHRSP, whereas pioglitazone combined with candesartan more attenuated p22(phox) and significantly reduced Nox1. Thus, additive suppression of cardiovascular NADPH oxidase by the combination was attributed to its additive attenuation of p22(phox) and Nox1 protein levels. In conclusion, we showed that pioglitazone protected against hypertensive cardiovascular damage, and the combination of pioglitazone and candesartan exerted more beneficial effects on hypertensive cardiovascular injury by more suppressing ROS.

Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Publishing Authors By Initials

T Nakamura,E Yamamoto,K Kataoka,T Yamashita,Y Tokutomi,YF Dong,S Matsuba,H Ogawa,S Kim-Mitsuyama,T Nakamura,E Yamamoto,K Kataoka,T Yamashita,Y Tokutomi,YF Dong,S Matsuba,H Ogawa,S Kim-Mitsuyama,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Hypertension

VOLUME: 51

Page Numbers: 296-301

Journal Abbreviation: Hypertension

ISSN: 1524-4563

DAY: 24

MONTH: 12

YEAR: 2007

Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7906255

Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.

AFFILIATION: Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjyo, Kumamoto 860-8556, Japan. kimmitsu@gpo.kumamoto-u.ac.jp.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Hypertension

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan Related Publications

• Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
• Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure.
• Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition.
• Overexpression of TNNI3K, a cardiac-specific MAP kinase, promotes P19CL6-derived cardiac myogenesis and prevents myocardial infarction-induced injury.
• Oxidation of Prx2 and phosphorylation of GRP58 by angiotensin II in human coronary smooth muscle cells identified by 2D-DIGE analysis.